10 minute read
ACE 2022 is Finally Here
Attend the long-awaited Aesthetics Conference and Exhibition on 11 & 12 March
Join your industry for the ultimate medical aesthetic learning experience The month of March is finally upon us, and with it brings the aesthetic event we have all be waiting for. ACE 2022 is finally happening, and this year, nothing will stop us! We are delighted that with restrictions lifted, and our speakers and brands prepped and raring to go, this year promises an aesthetics gathering like no other. With a packed agenda across five theatres confirmed, make sure you keep hold of your copy of the Agenda at a Glance inserted into this month’s journal to bring with you to the event, filled with all the must-see sessions! Planning your time at ACE is key, so check out the below summary for a whistle-stop tour of what’s on across the two incredible days!
Advertisement
TEOXANE delivers learning on dynamic filler, achieving natural outcomes and anatomical mapping Our Headline Sponsor TEOXANE is taking over the Main Auditorium to host two days of free educational content. In partnership with its international faculty, this impressive agenda reinforces the company’s dedication to providing exceptional world-class clinical education to aesthetic practitioners. The experts at TEOXANE are delivering essential learning and practice styles with demonstrations for delegates to witness, each followed by a case and outcome analysis.
Live demos in the Symposium agenda What better way to learn about the latest treatment styles than through up close and personal live demos? On Friday, the experts from Prollenium will give a full-face masterclass featuring Mr Mark Devlin, Dr Jo Ward and nurse prescriber Sharon Bennett. Galderma will then deliver insights into treating the eyes with Dr Munir Somji. Saturday will see Merz KOLs Mr Dalvi Humzah, Dr Simon and Emma Ravichandran, and Dr Paula Mann exploring key regions using ultrasound as the foundation of their treatment protocol.
Masterclass agenda – the best clinical education As if the previous two theatres weren’t enough, we have more live demonstrations from leading brands Allergan, Church Pharmacy, Croma, HA-Derma and SkinCeuticals in the Masterclass Agenda. Delegates will hear from expert KOLs on how to maximise
Dr Lee Walker Dr Wassim Taktouk • Soften and enhance using a natural and dynamic filler (temple, lateral brow and mid-face) with Dr Lee Walker – Friday 10:0012:30pm • Achieving natural outcomes in the middle third with Dr Lee Walker – Friday - 14:0016:00pm & Saturday 09:00-11:30am • Treating the lower third with combined indications with Dr Wassim Taktouk –
Saturday 13:00-15:30pm
results with the products and devices on offer, while enhancing the patient treatment experience from start to finish. Live demonstrations and interactive presentations will take place, covering topics that include chemical peels, microneedling, skin bioremodelling, polydeoxyribonucleotide injections and PRP. Speakers include aesthetic nurse prescriber Susan Young, Dr Rehanna Beckhurst, Dr Tracy Mountford, Dr Amiee Vyas, Dr Mayoni Gooneratne, Dr Daniel Sister and more.
Develop your clinic offering with the Expert Clinic agenda Join your aesthetic peers for engaging workshops led by top clinicians at the Expert Clinic. The agenda will feature specialist guidance on a huge range of aesthetic treatments, including dermal fillers, chemical peels, energy devices, skincare and more. Expect 30-minute sessions of live demonstrations and best practice advice on everything you need to know to develop your clinical offering. Aesthetic companies supporting the Expert Clinic include: AesthetiCare, AestheticSource, AnteAge, BTL Aesthetics, Celluma, Cutera, Erchonia Lasers, HA-Derma, Lynton Lasers, Neauvia, Venus Concept and Vivacy.
In Practice agenda – success for your clinic The new In Practice agenda, sponsored and supported by Enhance Insurance, will feature the latest business insights, tips and advice from experts across the field of aesthetic medicine. The key destination for all your business support requirements, this new channel educates via a dedicated conference, as well as through specific exhibitors at ACE and CCR to provide solutions and services. From social media, marketing, and diversifying your patient base, to launching new devices, enhancing your clinic and patient safety, there will be something for everyone to learn and discover.
CPD POINTS FOR EVERY SESSION YOU ATTEND!
Secure your FREE spot at ACE 2022 Attend the sessions that suit your learning needs the most and contribute to your clinical and business development. There are limited spaces available in both the TEOXANE and Symposium agendas so practitioners must pre-register for free online and arrive five minutes prior to the session start time.
Register now for ACE 2022
SCAN HERE TO REGISTER NOW
HEADLINE SPONSOR
11 & 12 MARCH 2022 / LONDON
EXHIBITION OPENING TIMES: • Friday 11 March: 9:00-17:30 • Saturday 12 March: 9:00-16:00
Your patients have the will. You can offer them the way.
Patients achieved signifi cant and sustained weight loss, in conjunction with reduced calorie intake and increased physical activity, in 1-year and 3-year trials vs placebo 1,2*
Similar to natural glucagon-like peptide-1, Saxenda® works to decrease appetite and thereby reduce food intake3†
This is not a real patient but only an illustration.
This material only relates to adult indication only. Please refer to SmPC for full indication.
Adults: Saxenda® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 (obesity) or ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. If you would like to request a visit from a representative please contact us on obesityuk@novonordisk.com For all product related enquiries please contact Novo Nordisk Customer Care Centre on 0800 023 2573.
†The exact mechanism of action is not entirely clear.
Prescribing Information
Please refer to the Saxenda® summary of product characteristics for full information. Saxenda® Liraglutide injection 3 mg. Saxenda® 6 mg/mL solution for injection in a pre-fi lled pen. One pre-fi lled pen contains 18mg liraglutide in 3mL. Indication: Adults: Saxenda® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of ≥ 30 kg/m² (obesity) or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. Adolescents (≥12 years): Saxenda® can be used as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of 12 years and above with obesity (BMI corresponding to ≥30 kg/m2 for adults by international cut-off points) and body weight above 60 kg. Posology and administration: Saxenda® is for once daily subcutaneous use only. Is administered once daily at any time, independent of meals. It is preferable that Saxenda® is injected around the same time of the day. Recommended starting dose is 0.6 mg once daily. Dose should be increased to 3.0 mg once daily in increments of 0.6 mg with at least one week intervals to improve gastro-intestinal (GI) tolerability. Treatment with Saxenda® in adults should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight. Daily doses higher than 3.0 mg are not recommended. No dose adjustment is required based on age but therapeutic experience in patients ≥75 years is limited and not recommended. No dose adjustment required for patients with mild or moderate renal impairment or mild or moderate hepatic impairment but it should be used with caution. Saxenda® for adolescents from the age of 12 to below 18 years old a similar dose escalation schedule as for adults should be applied. Treatment with Saxenda® in adolescents should be discontinued and re-evaluated if patients have not lost at least 4% of their BMI or BMI z score after 12 weeks on the 3.0mg/day or maximum tolerated dose. Saxenda® is not recommended for use in patients with severe renal impairment including endstage renal disease, or severe hepatic impairment or children below 12 years of age. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Special warnings and precautions for use: There is no clinical experience in patients with congestive heart failure New York Heart Association (NYHA) class IV and Saxenda® is not recommended for use in these patients. It is also not recommended in patients with eating disorders or treatment with medicinal products that may cause weight gain. Use of Saxenda® is not recommended in patients with infl ammatory bowel disease and diabetic gastroparesis since it is associated with transient GI adverse reactions including nausea, diarrhoea and vomiting. Acute pancreatitis has been observed with the use of GLP-1 receptor agonists, patients should be informed of the characteristic symptoms. If pancreatitis is suspected, Saxenda® should be discontinued. If acute pancreatitis is confi rmed, Saxenda® should not be restarted. In weight management clinical trials, a higher rate of cholelithiasis and cholecystitis was observed in patients on Saxenda® than those on placebo, therefore patients should be informed of characteristic symptoms. Thyroid adverse events such as goitre have been reported in particular in patients with pre-existing thyroid disease. Saxenda® should be used with caution in patients with thyroid disease. An increased risk in heart rate was observed in clinical trials. For patients who experience a clinically relevant sustained increase in resting heart rate, treatment with Saxenda® should be discontinued. There is a risk of dehydration in relation to GI side effects associated with GLP-1 receptor agonists. Precautions should be taken to avoid fl uid depletion. Patients with type 2 diabetes mellitus receiving Saxenda® in combination with insulin and/or sulfonylurea may have an increased risk of hypoglycaemia. Episodes of clinically signifi cant hypoglycaemia have been reported in adolescents (≥12 years) treated with liraglutide. Adolescents should be informed about the characteristic symptoms of hypoglycaemia and the appropriate actions. Fertility, pregnancy and lactation: Saxenda® should not be used during pregnancy. If a patient wishes to become pregnant, or pregnancy occurs, treatment with Saxenda® should be discontinued. It should not be used during breast-feeding. Undesirable effects: Very common (≥1/10); nausea, vomiting, diarrhoea, constipation. Common (≥1/100 to <1/10); hypoglycaemia, insomnia, dizziness, dysgeusia, dry mouth, dyspepsia, gastritis, gastro-oesophageal refl ux disease, abdominal pain upper, fl atulence, eructation, abdominal distension, cholelithiasis, injection site reactions, asthenia, fatigue, increased lipase, increased amylase. Uncommon (≥1/1,000 to <1/100); dehydration, tachycardia, pancreatitis, cholecystitis, urticaria, malaise, delayed gastric emptying Rare (≥1/10,000 to <1/1,000); anaphylactic reaction, acute renal failure, renal impairment. The Summary of Product Characteristics should be consulted for a full list of side effects. MA numbers and Basic NHS Price : 5 x 3 ml pre-fi lled pens £196.20 NI: EU/1/15/992/003 GB : PLGB 04668/0409 Legal category: POM. Full prescribing information can be obtained from: Novo Nordisk Limited, 3 City Place, Beehive Ring Road, Gatwick, West Sussex, RH6 0PA. Marketing Authorisation Holder: Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark. Date last revised: October 2021
* In the 1 year trial patients taking Saxenda® (n=2487) had a baseline body weight of 106.2 kg. Completers’ (n=2437) mean weight loss at week 56 of treatment was 8.4 kg. Patients taking placebo (n=1244) had a baseline body weight of 106.2 kg. Completers’ (n=1225) mean weight loss at week 56 of treatment was 2.8 kg1, p<0.001. In the 3 year trial Patients taking Saxenda® (n=1505) had a baseline body weight of 107.5 kg. Completers’ (n=1472) mean weight loss at week 160 of treatment was 6.5 kg. Patients taking placebo (n=749) had a baseline body weight of 107.9 kg. Completers’ (n=738) mean weight loss at week 160 of treatment was 2.0kg2, p<0.0001. References: 1. Pi-Sunyer X, Astrup A, Fujioka K, et al; for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomised, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. 2. le Roux CW, Astrup A, Fujioka K, et al; for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-1409. 3. Saxenda® Summary of product characteristics, NI&GB. Bagsvard, Denmark: Novo Nordisk A/S.
